Showing 7631-7640 of 8826 results for "".
- High Kissability Marks for Restylane Kysse in New Phase 4 Studyhttps://practicaldermatology.com/news/high-kissability-marks-for-restylane-kysse-in-new-phase-4-study/2460465/In a recent first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, subject satisfaction as well as partner satisfaction were evaluated following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a
- New Infographic Compares Rashes to COVID Toeshttps://practicaldermatology.com/news/new-infographic-compare-rashes-to-covid-toes/2460461/A new infographic from First Derm compares and contrasts rashes associated with COVID-19.
- Skin of Color Update Goes Virtual for 2020https://practicaldermatology.com/news/skin-of-color-update-goes-virtual-for-2020/2460459/Skin of Color Update’s 2020 event is going virtual. The largest medical education event focused on the dermatologic treatment of skin of color will be held September 12-13. The Skin of Color Update agenda has been modified to reflect virtual learning. Live session
- Mount Sinai Researcher Receives NIH Grant to Study Immune Responses of Patients With Inflammatory Skin Diseases in the Setting of COVID-19https://practicaldermatology.com/news/mount-sinai-researcher-receives-nih-grant-to-study-immune-responses-of-patients-with-inflammatory-skin-diseases-in-the-setting-of-covid-19/2460458/Patients with moderate to severe atopic dermatitis who take a biologic treatment such as dupilumab seem to be protected from developing serious complications of COVID-19 and are also less likely to be hospitalized due to complications. Now, researchers from the Icahn School of Medicine
- Phase 2 Studies: Revance’s DaxibotulinumtoxinA for Injection Looks Good for Forehead Lines, Crow’s Feethttps://practicaldermatology.com/news/phase-2-studies-revances-daxibotulinumtoxina-for-injection-looks-good-for-forehead-lines-and-crows-feet/2460456/Revance Therapeutics, Inc.’s next-generation neuromodulator product, DaxibotulinumtoxinA, safely and effectively smoothed forehead lines and crow’s feet with a median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet achieved in at least one treatment group
- ISD Survey: Climate Change Is A Real Threat to Skin Healthhttps://practicaldermatology.com/news/isd-survey-climate-change-is-a-real-threat-to-skin-health/2460451/The vast majority of dermatologists (95.6 percent) believe climate change is occurring and 88.6 percent indicated that climate change will impact the incidence of skin diseases in their areas, according to an online survey was conducted by the International Society of Dermatology's (ISD)
- Cynosure Reopening Survey: If You Wear Masks, They Will Come Backhttps://practicaldermatology.com/news/cynosure-reopening-survey-if-you-wear-masks-they-will-come-back/2460441/Fully 85 percent of people plan to return to aesthetic treatments within 12 months of COVID-19 restrictions being lifted, and 63 percent plan to return to practices within just three months of restrictions being lifted in their respective countries, according to a
- New Phase 3 Data for Tremfya Show Consistent, High Levels of Skin Clearance Through Four Years in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-phase-3-data-for-tremfya-show-consistent-high-levels-of-skin-clearance-through-four-years-in-moderate-to-severe-plaque-psoriasis/2460431/New long-term plaque psoriasis data for The Janssen Pharmaceutical Companies of Johnson & Johnson's Tremfya (guselkumab) show consistent, high levels of skin clearance at week 100 and week 204 (four years). In the open-label extension of VOYAGE 2, at four years, 80 percent of pa
- Phase 3 Study Finds Twice-Weekly Enstilar Foam Safe and Effective for Long-Term Maintenance Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/phase-3-study-finds-twice-weekly-enstilar-foam-safe-and-effective-for-long-term-maintenance-treatment-of-plaque-psoriasis/2460427/LEO Pharma A/S presented results from the Phase 3 PSO-LONG clinical tria, which compared the efficacy and safety of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) Foam versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.
- Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumabhttps://practicaldermatology.com/news/bimekizumab-phase-3-data-show-superior-skin-clearance-in-moderate-to-severe-psoriasis/2460421/UCB shared first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior